

PlexCMV

Intended Use: PlexCMV is a blood test to measure the level of cellular immunity to Cytomegalovirus (CMV). Decreased anti-CMV immunity increases the risk of CMV infection.*

Purpose: Knowledge about immunity to CMV and therefore the risk of CMV infection can be combined with available clinical data to plan additional treatment for your patient

Procedure: PlexCMV measures functional cell-mediated immunity to CMV.

- Whole blood, 1-2 ml from children, 2-3 ml from adults in sodium heparin green top tubes, shipped at ambient temperature overnight to Plexision's reference laboratory
- CMV-specific T-cells and their subsets, which express the inflammatory marker, CD154 are measured after stimulation with CMV antigen.
- Simultaneously, recipient T-cell stimulation with mitogen measures general T-cell responsiveness.

Performance: Results

- **Are reported within 6 hours** after blood samples reach the laboratory
- are reported as frequencies of CMV-specific T-cells and their subsets along with thresholds for the level of CMV immunity. These thresholds have been established from studies of over 150 transplant recipients. These thresholds determine whether immunity to CMV is decreased or not.
- Negative predictive value is 91-94%.

References: US Patent 9606109 *PlexCMV is not FDA-approved

Ste 202, 4424 Penn Avenue, Pittsburgh, PA, 15217. Ph: 412-224-2507. Fax: 412-224-2706. www.plexision.com